
Home
Chapter Home
Jobs
Conferences
Fellowships
Books
Advertisement
Breast malignant, males, children
Carcinoma subtypes
Pleomorphic variant of lobular carcinoma
Reviewer: Monika Roychowdhury, M.D., (see Reviewers
page)
Revised: 14 November 2012, last major update August 2012
Copyright: (c) 2001-2012, PathologyOutlines.com, Inc.
General
=========================================================================
● Aggressive variant with high grade tumor cells
Epidemiology
=========================================================================
● Mean age 57 years, range 24-92 years
Clinical features
=========================================================================
● Presents at more advanced stage than classic lobular carcinoma
(J Surg Oncol 2008;98:314)
● Traditionally considered to have aggressive clinical course
(Am J Surg Pathol 2000;24:1650) but see Ann Diagn Pathol 2012;16:185
● Poorer clinical outcome: older patients, negative hormonal receptor status
Gross images
=========================================================================
Micro description
=========================================================================
● Multifocal nodular aggregates of dyscohesive, pleomorphic, high-grade tumor cells in dense fibrotic breast parenchyma
● Also single file and targetoid pattern of classic lobular carcinoma
● Often signet ring cells (29%), globoid plasmacytoid cells with eosinophilic or foamy or vacuolated cytoplasm, high nuclear grade and often multiple nucleoli
● Pleomorphic LCIS (45%) and classic LCIS (21%) often present
● 3-10 mitoses per 10 HPF
● Usually no microcalcifications, no duct formation present
Micro images
=========================================================================
Pleomorphic tumor cells
Signet ring type cells
With pleomorphic LCIS
Contributed by Dr. Semir Vranic
E-cadherin negative (staining of residual normal ducts), by Dr. Semir Vranic
p53
Other images: pleomorphic tumor cells, E-cadherin negative
Cytology description
=========================================================================
● More cellular than classic lobular, large tumor cells with single filing, tumor cells have cytoplasmic vacuoles and pleomorphic nuclei
(Cancer 1997;81:29)
● May have apocrine features and resemble atypical mesothelial cells
(Diagn Cytopathol 2008;36:657)
● Ductal lavage: similar features, although less striking, including epithelial cells in small clusters, single-file or isolated; also nuclear atypia, cytoplasmic vacuoles and signet ring features
(Acta Cytol 2008;52:207)
Cytology images
=========================================================================
Virtual slides
=========================================================================
Positive stains
=========================================================================
● GCDFP-15 (71%, due to apocrine nature), HER2 (2+ to 3+ in 81%), p53 (48%)
● Variable ER and PR
Negative stains
=========================================================================
● E-cadherin
(Mod Pathol 2003;16:674), beta-catenin (membrane staining is absent,
Appl Immunohistochem Mol Morphol 2007;15:260)
● 13% are triple negative (Histopathology 2012;61:365)
Molecular / cytogenetic description
=========================================================================
● Resembles infiltrating lobular carcinoma more than infiltrative ductal carcinoma
(J Pathol 2008;215:231)
● Frequent gains on 1q and 16p, losses on 11q and 16q, and genomic amplifications of 8q24, 11q13, 12q13, 17q12 and 20q13
(Future Oncol 2009;5:233)
● More frequent p53 mutations than classic lobular (Cell Oncol (Dordr) 2012;35:111)
Differential diagnosis
=========================================================================
● Chemotherapy or radiation treatment effect
Additional references
=========================================================================
● Hum Pathol 1992;23:1167,
Hum Pathol 1992;23:655,
Mod Pathol 1998;11:814
End of Breast malignant, males, children > Carcinoma subtypes > Pleomorphic variant of lobular carcinoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com
with any questions (click here for other
contact information).